Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 68 articles: HTML format

Single Articles

November 2026
1. LI D, Zhou Z, Liang G, Zeng D, et al
   Association Between Allostatic Load, Genetic Susceptibility, and Liver Cancer Incidence: A Large-Scale Prospective Cohort Study.
   Int J Cancer. 2026;159:2158-2169.
   PubMed     Abstract available
   
   
   October 2026
2. ROSE F, El-Ekiaby N, Wehling L, Weiler SME, et al
   A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.
   Int J Cancer. 2026;159:1829-1843.
   PubMed     Abstract available
   
   
   September 2026
3. LEE J, Kim HJ, Park SJ, Park S, et al
   Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort.
   Int J Cancer. 2026 Sep 1. doi: 10.1002/ijc.70725.
   PubMed     Abstract available
   
   
   August 2026
4. LIU D, Xu B, Huang D, Sun Z, et al
   Liver metastasis ablation combined with PD-1 inhibitors improves immunotherapy efficacy: A multicenter cohort study.
   Int J Cancer. 2026;159:951-959.
   PubMed     Abstract available
   
   
   
5. HERNANDEZ BY, Zhu X, Macatugal E, Nagata M, et al
   Cyanotoxin exposure as a novel risk factor for liver fibrosis and steatosis.
   Int J Cancer. 2026;159:864-875.
   PubMed     Abstract available
   
   
   July 2026
6. HE D, Zeng X, Yin L, Liu Y, et al
   Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients.
   Int J Cancer. 2026 Jul 3. doi: 10.1002/ijc.70633.
   PubMed     Abstract available
   
   
   June 2026
7. SONG M, Wang X, Liang J, Wang L, et al
   The CXCL12-CXCR4/CXCR7 axis as a therapeutic target in liver cancer: Enhancing immune evasion and the future of combination therapies.
   Int J Cancer. 2026;158:3065-3079.
   PubMed     Abstract available
   
   
   
8. ZHANG D, Xie Q, Zhang Z, Wang S, et al
   Real-World Evidence on the Efficacy of Icaritin for Unresectable Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
   Int J Cancer. 2026 Jun 11. doi: 10.1002/ijc.70590.
   PubMed     Abstract available
   
   
   
9. ZHAO J, Li K, Zhang Y, Chen Y, et al
   Liver Cancer Risk and Incidence Attributable to Human Immunodeficiency Virus: A Meta-Analysis and Population-Attributable Modeling Study of Over 1.2 Million Individuals.
   Int J Cancer. 2026 Jun 11. doi: 10.1002/ijc.70587.
   PubMed     Abstract available
   
   
   May 2026
10. ZHANG X, Zhao L, Campbell PT, Chen Y, et al
    The impact of genetic and environmental risk factors on adverse liver outcomes.
    Int J Cancer. 2026;158:2317-2328.
    PubMed     Abstract available
    
    
    April 2026
11. LIU J, Tang M, Xuan J, Tang T, et al
    Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma.
    Int J Cancer. 2026 Apr 21. doi: 10.1002/ijc.70495.
    PubMed     Abstract available
    
    
    
12. WATLING CZ, Campbell PT, Graubard BI, Wang Y, et al
    Pre-diagnostic immunological markers of bacterial translocation and liver cancer risk: A nested case-control analysis of 12 prospective cohorts.
    Int J Cancer. 2026;158:1801-1812.
    PubMed     Abstract available
    
    
    March 2026
13. CAI Z, Qiu L, Li L, Li Z, et al
    Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma.
    Int J Cancer. 2026 Mar 16. doi: 10.1002/ijc.70445.
    PubMed     Abstract available
    
    
    
14. KASTELEINER P, Grozinger G, Schmehl J, Flatz L, et al
    Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70418.
    PubMed     Abstract available
    
    
    February 2026
15. YU C, Wan J, Jin C, Li C, et al
    Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases.
    Int J Cancer. 2026 Feb 25. doi: 10.1002/ijc.70405.
    PubMed     Abstract available
    
    
    
16. SCOTT KJ, West EJ, Brownlie RJ, Ismail F, et al
    Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.
    Int J Cancer. 2026 Feb 16. doi: 10.1002/ijc.70386.
    PubMed     Abstract available
    
    
    January 2026
17. SPEHNER L, Bouard A, El Kaddissi A, Kroemer M, et al
    Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.
    Int J Cancer. 2026;158:182-192.
    PubMed     Abstract available
    
    
    December 2025
18. ALI E, Ye W, Pavlov S, Cervenkova L, et al
    Distribution and prognostic value of T-cells in primary colorectal cancer and adjacent non-tumor mucosa in stage IV versus stage I-III patients.
    Int J Cancer. 2025 Dec 30. doi: 10.1002/ijc.70319.
    PubMed     Abstract available
    
    
    
19. DE SALINS V, Martinez-Tapia C, Gay P, Morel A, et al
    The Fibrosis-4 score is associated with overall mortality and severe haematological toxicity in older patients with cancer: Analysis of two prospective cohort studies.
    Int J Cancer. 2025;157:2506-2520.
    PubMed     Abstract available
    
    
    
20. CHAI X, Chen J, Zhao Y, Chu W, et al
    G9a epigenetically suppresses CXCL10 expression and inhibits anti-tumor immunity in hepatocellular carcinoma.
    Int J Cancer. 2025 Dec 9. doi: 10.1002/ijc.70284.
    PubMed     Abstract available
    
    
    
21. LUO S, Qiao S, Liu L, Jia Y, et al
    Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers.
    Int J Cancer. 2025;157:2309-2324.
    PubMed     Abstract available
    
    
    November 2025
22. PHAM YT, Yuan JM, Luu HN
    Reply to 'Comment on "Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study"'.
    Int J Cancer. 2025 Nov 28. doi: 10.1002/ijc.70241.
    PubMed    
    
    
    
23. ZAHEDIAN A, Hejazian E, Barary M, Ranaee M, et al
    Comments on "Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study".
    Int J Cancer. 2025 Nov 28. doi: 10.1002/ijc.70242.
    PubMed    
    
    
    
24. LAUKHUF J, Wiens L, Grozinger G, Dittmann H, et al
    Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021.
    Int J Cancer. 2025 Nov 11. doi: 10.1002/ijc.70246.
    PubMed     Abstract available
    
    
    
25. SHEN QM, Li ZY, Wang J, Zou YX, et al
    Prediagnostic plasma metabolite concentrations and liver cancer risk: A nested case-control study with long follow-up in the Shanghai Women's Health Study.
    Int J Cancer. 2025;157:1805-1817.
    PubMed     Abstract available
    
    
    
26. SHEN Q, Shi S, Wang H, Zhang S, et al
    Serum 25-hydroxyvitamin D, vitamin D-related variants, and risk of chronic liver disease.
    Int J Cancer. 2025;157:1781-1794.
    PubMed     Abstract available
    
    
    October 2025
27. ZHENG Y, Han J, Qu Y, Wang J, et al
    Circulating cell-free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV-positive Nigerian population.
    Int J Cancer. 2025 Oct 23. doi: 10.1002/ijc.70204.
    PubMed     Abstract available
    
    
    
28. YANG Z, Wang L, Kang F
    Immunogenic cell death: A promising mechanism involving different therapeutic strategies for liver cancer.
    Int J Cancer. 2025;157:1267-1276.
    PubMed     Abstract available
    
    
    September 2025
29. HAN Y, Shaw VR, Byun J, Thrift AP, et al
    Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits.
    Int J Cancer. 2025 Sep 27. doi: 10.1002/ijc.70136.
    PubMed     Abstract available
    
    
    
30. VAN DER GEEST LG, van der Mark M, Verheij J, Farina Sarasqueta A, et al
    Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry.
    Int J Cancer. 2025 Sep 12. doi: 10.1002/ijc.70145.
    PubMed     Abstract available
    
    
    August 2025
31. RAJTMAJEROVA M, Ambrozkiewicz F, Hlavac V, Trailin A, et al
    Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases.
    Int J Cancer. 2025 Aug 30. doi: 10.1002/ijc.70116.
    PubMed     Abstract available
    
    
    
32. GUERRERO JJG, Encarnacion PC, Del Rosario MAS, Ora MAS, et al
    Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
    Int J Cancer. 2025 Aug 20. doi: 10.1002/ijc.70092.
    PubMed     Abstract available
    
    
    
33. ZHAO L, Cheng J, Zheng Y, Wu J, et al
    Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70091.
    PubMed     Abstract available
    
    
    
34. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    PubMed     Abstract available
    
    
    July 2025
35. HUANG F, Jiang H, Shen M, Zhang C, et al
    Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.
    Int J Cancer. 2025 Jul 22. doi: 10.1002/ijc.70055.
    PubMed     Abstract available
    
    
    
36. AIELLO C, Felli E, Musarra T, Nevi L, et al
    Rewriting the MASLD-associated hepatocellular carcinoma script: Targeting epigenetics and metabolism.
    Int J Cancer. 2025 Jul 22. doi: 10.1002/ijc.70047.
    PubMed     Abstract available
    
    
    
37. PHAM YT, Wang R, Behari J, Chen GC, et al
    Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study.
    Int J Cancer. 2025 Jul 19. doi: 10.1002/ijc.70057.
    PubMed     Abstract available
    
    
    
38. YU C, Lin F, Tian C, Guo H, et al
    Baseline vitamin D status, genetic susceptibility, and the risk of incident hepatocellular carcinoma.
    Int J Cancer. 2025 Jul 3. doi: 10.1002/ijc.70003.
    PubMed     Abstract available
    
    
    June 2025
39. PASSEN CV, Krug J, Weiss L, Abdou MM, et al
    Integrin beta6 expression in colorectal cancer cells promotes liver metastasis through enhanced adhesion to endothelial fibronectin.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35504.
    PubMed     Abstract available
    
    
    May 2025
40. PATEL DP, Loffredo CA, Pupacdi B, Rabibhadana S, et al
    Associations of chronic liver disease and liver cancer with glyphosate and its metabolites in Thailand.
    Int J Cancer. 2025;156:1885-1897.
    PubMed     Abstract available
    
    
    March 2025
41. AGLAGO EK, Ramos I, Keski-Rahkonen P, Chatziioannou C, et al
    Alcohol and smoking habits in association with hepatocellular carcinoma risk.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35401.
    PubMed     Abstract available
    
    
    
42. GAO Y, Cheng AL, Li LX, Parent N, et al
    Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35407.
    PubMed     Abstract available
    
    
    
43. JIANG X, Zhang Q, Zheng Z, Shen Z, et al
    Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.
    Int J Cancer. 2025 Mar 12. doi: 10.1002/ijc.35399.
    PubMed     Abstract available
    
    
    
44. CHIVITE-LACABA M, Justo I, Utrero-Rico A, Caso O, et al
    Delineation of monocytic and early-stage myeloid-derived suppressor cells in the peripheral blood of patients with hepatocarcinoma.
    Int J Cancer. 2025 Mar 7. doi: 10.1002/ijc.35390.
    PubMed     Abstract available
    
    
    January 2025
45. HE M, Xie W, Yuan Z, Chen J, et al
    Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35341.
    PubMed     Abstract available
    
    
    December 2024
46. HUANG M, Song C, Zhou X, Wang H, et al
    Tissue-matched analysis of MRI evaluating the tumor infiltrating lymphocytes in hepatocellular carcinoma.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35281.
    PubMed     Abstract available
    
    
    
47. REMOND M, Smolenschi C, Tarabay A, Gelli M, et al
    Clinical and molecular features of early onset pancreatic adenocarcinoma.
    Int J Cancer. 2024;155:1969-1981.
    PubMed     Abstract available
    
    
    November 2024
48. TRAILIN A, Ali E, Ye W, Pavlov S, et al
    Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35252.
    PubMed     Abstract available
    
    
    
49. WATLING CZ, Kelly RK, Watts EL, Graubard BI, et al
    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35244.
    PubMed     Abstract available
    
    
    October 2024
50. LIU J, Zhang X, Lin J, Dai C, et al
    HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35224.
    PubMed     Abstract available
    
    
    September 2024
51. HO NT, Abe SK, Rahman MS, Islam R, et al
    Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium.
    Int J Cancer. 2024;155:854-870.
    PubMed     Abstract available
    
    
    August 2024
52. HUANG H, Zhao Y, Deng Y, Zhan Z, et al
    Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study.
    Int J Cancer. 2024 Aug 26. doi: 10.1002/ijc.35139.
    PubMed     Abstract available
    
    
    
53. BUI TT, Park E, Kang HY, Oh JK, et al
    Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case-control study in South Korea.
    Int J Cancer. 2024;155:654-665.
    PubMed     Abstract available
    
    
    July 2024
54. VAZ J, Jepsen P, Stromberg U, Midlov P, et al
    Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35097.
    PubMed     Abstract available
    
    
    June 2024
55. ZHAO L, Zhang X, Birmann BM, Danford CJ, et al
    Pre-diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population-based cohort studies from the United States and the United Kingdom.
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35054.
    PubMed     Abstract available
    
    
    
56. KARA-ALI GH, Cano L, Dion S, Imerzoukene G, et al
    Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
    Int J Cancer. 2024;154:1999-2013.
    PubMed     Abstract available
    
    
    May 2024
57. PUPACDI B, Loffredo CA, Budhu A, Rabibhadana S, et al
    The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand.
    Int J Cancer. 2024 May 18. doi: 10.1002/ijc.35034.
    PubMed     Abstract available
    
    
    
58. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
    N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
    Int J Cancer. 2024;154:1857-1868.
    PubMed     Abstract available
    
    
    February 2024
59. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
    Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
    Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
    PubMed     Abstract available
    
    
    
60. YU Z, Bai X, Zhou R, Ruan G, et al
    Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019.
    Int J Cancer. 2024;154:615-625.
    PubMed     Abstract available
    
    
    
61. XU FQ, Xu QY, Zhu ZJ, Jin L, et al
    Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study.
    Int J Cancer. 2024;154:530-537.
    PubMed     Abstract available
    
    
    
62. JIANG L, Zhao N, Xu M, Pei J, et al
    Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis.
    Int J Cancer. 2024;154:465-476.
    PubMed     Abstract available
    
    
    
63. BARUPAL DK, Ramos ML, Florio AA, Wheeler WA, et al
    Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.
    Int J Cancer. 2024;154:454-464.
    PubMed     Abstract available
    
    
    January 2024
64. ZHAO G, Shi X, Zhang L, Liang H, et al
    Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
    PubMed    
    
    
    
65. KIM MN, Zhang X, Ahn SH
    Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
    PubMed    
    
    
    November 2023
66. ROSSARI F, Tada T, Suda G, Shimose S, et al
    alpha-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Int J Cancer. 2023 Nov 23. doi: 10.1002/ijc.34799.
    PubMed     Abstract available
    
    
    October 2023
67. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    PubMed     Abstract available
    
    
    
68. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum